摘要
目的研究干扰素α-1b(Interferonα-1b,IFNα-1b)联合阿昔洛韦治疗对传染性单核细胞增多症(Infectious mononucleosis,IM)患儿EBV-DNA拷贝数转阴率及T淋巴细胞亚群的影响。方法收集2018年5月至2021年5月在本院进行治疗的103例IM患儿的临床资料进行本次研究。按照不同治疗方式列为研究组(n=52,IFNα-1b联合阿昔洛韦治疗)和对照组(n=51,阿昔洛韦治疗)。比较两组EBV-DNA拷贝数转阴率、T淋巴细胞亚群水平及不良反应情况。结果(1)研究组患者EBV-DNA拷贝数转阴率(96.15%)显著高于对照组患者EBV-DNA拷贝数转阴率(78.43%),差异具有统计学意义(P<0.05)。(2)治疗后,两组CD^(3+)、CD^(8+)较治疗前降低,CD^(4+)、CD^(4+)/CD^(8+)较治疗前升高,且以研究组变化最为明显,差异具有统计学意义(P<0.05)。(3)研究组不良反应率为11.54%,对照组不良反应率为7.84%,两组对比差异不具有统计学意义(P>0.05)。结论?IFNα-1b联合阿昔洛韦治疗IM患儿的效率高,能够有效改善患者的T淋巴细胞亚群水平,且具有一定安全性,值得推广使用。
Objective To study the effects of interferonα-1b (IFNα-1b) combined with acyclovir treatment on the negative conversion ratio of EBV-DNA copy number and T lymphocyte subsets in children with infectious mononucleosis (IM).Methods The clinical data of 103 children with IM who were treated in this hospital from May 2018 to May 2021 were collected for this study.According to different treatment methods,they were classified into the study group (n=52,IFNα-1b combined with acyclovir treatment) and the control group (n=51,acyclovir treatment).The negative conversion ratio of EBV-DNA copy number,the level of T lymphocyte subsets and adverse reactions between the two groups were compared.Results (1) The negative conversion rate of EBV-DNA copy number in the study group (96.15%) was significantly higher than that in the control group (78.43%),and the difference was statistically significant (P<0.05).(2) After treatment,CD^(3+)and CDCD^(8+) in the two groups were lower than those before treatment,and CD^(4+),CD^(4+)/CD^(8+)were higher than those before treatment.The changes in the study group were the most obvious,and the difference was statistically significant (P<0.05).(3) The adverse reaction rate of the study group was 11.54% and that of the control group was 7.84%.The difference between the two groups was not statistically significant (P>0.05).Conclusion IFNα-1b combined with acyclovir is highly effective in the treatment of children with IM,can effectively improve the level of T lymphocyte subsets in patients,and has some safety,which is worthy of promotion.
作者
赵代艳
王静
苏爱芳
郭长根
Zhao Dai-yan;Wang Jing;SuAi-fang;Guo Chang-gen(Department of Pediatrics,Second People's Hospital of Luohe City,Luohe,Henan 462000)
出处
《国外医药（抗生素分册）》
CAS
2022年第1期53-55,共3页
World Notes on Antibiotics
